

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



杭州启明醫療器械股份有限公司  
**Venus Medtech (Hangzhou) Inc.**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2500)**

**(1) ADDITIONAL RESUMPTION GUIDANCE; AND  
(2) CONTINUED SUSPENSION OF TRADING**

This announcement is made by Venus Medtech (Hangzhou) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated May 8, 2023, August 4, 2023, November 23, 2023, November 27, 2023, December 27, 2023 and February 7, 2024 in relation to, amongst others, the suspension of trading in the shares of the Company, the initial resumption guidance provided by the Stock Exchange, and the passing away of Mr. Wan Yee Joseph Lau (previously an independent non-executive director of the Company). Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as defined in the abovementioned announcements.

**ADDITIONAL RESUMPTION GUIDANCE**

Further to the resumption guidance for the resumption of trading in the shares of the Company provided by the Stock Exchange on December 20, 2023, the Company received a letter from the Stock Exchange on February 9, 2024, pursuant to which, the Stock Exchange has handed down an additional resumption guidance (see resumption guidance (e) below) to the Company following the passing away of Mr. Wan Yee Joseph Lau. Together with the resumption guidance previously provided by the Stock Exchange, details of all resumption guidance (collectively, the “**Resumption Guidance**”) are as follows:

- (a) conduct the Special Audit and an appropriate forensic investigation into (i) the provision of loans to Mr. Zi and Mr. Zeng and (ii) other fund flows of the Group to and from Mr. Zi, Mr. Zeng and/or any entity they, individually or collectively, own or control that may be uncovered by the Special Audit, announce the findings, and take appropriate remedial actions;
- (b) conduct an independent internal control review and demonstrate that the Company has in place adequate internal controls and procedures to comply with the Listing Rules;

- (c) demonstrate that there is no reasonable regulatory concern about the management integrity and/or the integrity of any persons with substantial influence over the Company's management and operations, which will pose a risk to investors and damage market confidence;
- (d) inform the market of all material information for the Shareholders and investors to appraise its position; and
- (e) re-comply with Rules 3.10(1), 3.10A, 3.21 and 3.27A of the Listing Rules in relation to the composition and chairmanship of the Board and its Board committees, as applicable.

The Stock Exchange further indicates that it may modify the Resumption Guidance and/or give further guidance as and when appropriate.

### **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on November 23, 2023 and will remain suspended pending the fulfillment of the Resumption Guidance as specified by the Stock Exchange.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Venus Medtech (Hangzhou) Inc.**  
**Mr. Lim Hou-Sen (Lin Haosheng)**  
*Executive Director*

Hangzhou, February 16, 2024

*As at the date of this announcement, the executive Directors are Mr. Lim Hou-Sen (Lin Haosheng), Mr. Liqiao Ma and Ms. Meirong Liu; the non-executive Directors are Mr. Ao Zhang and Mr. Wei Wang; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu and Mr. Chi Wai Suen.*